Automate Your Wheel Strategy on CVS
With Tiblio's Option Bot, you can configure your own wheel strategy including CVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CVS
- Rev/Share 300.5234
- Book/Share 61.1499
- PB 1.0956
- Debt/Equity 1.0557
- CurrentRatio 0.8227
- ROIC 0.0403
- MktCap 84553936800.0
- FreeCF/Share 4.7113
- PFCF 14.2323
- PE 15.9631
- Debt/Assets 0.3178
- DivYield 0.0398
- ROE 0.0698
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CVS | Leerink Partners | Market Perform | Outperform | $55 | $75 | Feb. 13, 2025 |
| Upgrade | CVS | Cantor Fitzgerald | Neutral | Overweight | -- | -- | Feb. 12, 2025 |
| Upgrade | CVS | Edward Jones | Hold | Buy | -- | -- | Jan. 30, 2025 |
| Upgrade | CVS | Deutsche Bank | Hold | Buy | -- | $66 | Dec. 3, 2024 |
| Upgrade | CVS | Barclays | Equal Weight | Overweight | $63 | $82 | Oct. 10, 2024 |
| Upgrade | CVS | TD Cowen | Hold | Buy | $59 | $85 | Oct. 4, 2024 |
News
CVS CEO defends pharmacy middlemen, accuses drugmakers of 'monopolistic' practices
Published: February 12, 2025 by: CNBC
Sentiment: Negative
CVS Health CEO David Joyner defended controversial pharmacy middlemen, who are widely accused of inflating prescription medication prices, and instead accused manufacturers of "monopolistic" practices that keep drug costs high in the U.S. Joyner, who stepped into the role in October, spent much of his opening remarks on the company's fourth-quarter earnings call discussing so-called pharmacy benefit managers, or PBMs.
Read More
Trade Tracker: Joe Terranova buys CVS and Alibaba
Published: February 12, 2025 by: CNBC Television
Sentiment: Positive
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to explain why he's buying these two stocks at these levels.
Read More
Why CVS Health Stock Popped Today
Published: February 12, 2025 by: The Motley Fool
Sentiment: Positive
Shares of CVS Health (CVS 13.66%) were soaring Wednesday after the diversified healthcare giant's fourth-quarter results topped estimates and management offered better-than-expected guidance for 2025.
Read More
CVS Beats EPS Estimates, Losses Loom
Published: February 12, 2025 by: The Motley Fool
Sentiment: Positive
CVS Health (CVS 13.34%), a leading integrated healthcare and pharmacy solutions provider, released its fourth-quarter 2024 earnings on February 12, 2025.
Read More
CVS Stock Approaches Q4 Earnings With Resistance In Sight
Published: February 11, 2025 by: Benzinga
Sentiment: Neutral
CVS Health Corp CVS will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects 94 cents in EPS and $97.20 billion in revenues as the company reports before market hours.
Read More
What's a Fair Price for CVS Stock?
Published: February 11, 2025 by: The Motley Fool
Sentiment: Neutral
CVS (CVS 1.23%) is struggling to stay relevant amid rising costs and declining customer visits.
Read More
Dividend Roundup: Why CVS Health Is Still Better Than Walgreens
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Negative
Investors drawn to WBA and CVS must feel disappointed. WBA's recent dividend suspension and CVS's dividend freeze reflect financial headwinds and operational challenges. I won't consider either as a buy candidate.
Read More
About CVS Health Corporation (CVS)
- IPO Date 1996-11-20
- Website https://www.cvshealth.com
- Industry Medical - Healthcare Plans
- CEO Mr. J. David Joyner CEBS
- Employees 219000